The updated research framework for AD, proposed by the National Institute of Aging-Alzheimer’s Association (NIA-AA) Work Group, emphasizes the importance of incorporating biomarkers in AD research and defines AD as a biological tau, amyloid, and neurodegeneration (ATN) entity (Rawan Tarawneh, 2020). Here, MAPT is linked to Alzheimer disease.